Loading...
•
Mar 31, 2020
AptarGroup Q1 2020 Earnings Report
AptarGroup's Q1 2020 results were reported.
Key Takeaways
AptarGroup's Q1 2020 results showed a decrease in reported sales by 3% to $722 million, with core sales, excluding currency and acquisition effects, decreasing by 2%. EPS was $0.84, a decrease of 13% compared to the prior year. The Pharma segment saw core sales growth of 7%, offsetting declines in other segments. The company is deemed an essential supplier and is monitoring the COVID-19 pandemic's impact.
Reported sales decreased 3% due to currency exchange rates, lower resin costs, and COVID-19 impacts.
Core sales, excluding currency and acquisition effects, decreased 2%.
Pharma segment core sales grew 7%, offsetting declines in other segments.
Adjusted earnings per share totaled $0.93, an 11% decrease year-over-year.
AptarGroup
AptarGroup
AptarGroup Revenue by Segment
Revenue by Segment
Aptar Pharma Revenue
CapyFin.comAptar Beauty Revenue
CapyFin.comAptar Closures Revenue
CapyFin.com Forward Guidance
Aptar expects the coming quarter to mark the worst of the expected COVID-19 impacts on our business and we anticipate a gradual recovery in the second half of the year.
Positive Outlook
- Broad portfolio of dispensing, drug delivery and active packaging solutions
- Growing services platforms
- New partnerships
- Balance sheet remains in excellent condition
- Continue to diligently manage costs and capacities
Challenges Ahead
- Duration and severity of the COVID-19 pandemic
- Pace and scope of reopening in regions that are currently under government confinement orders
- Speed at which beauty and other retail stores open
- Willingness of consumers to participate in those shopping channels
- Rate at which airline travel will resume and the general level of on-the-go consumption
Revenue & Expenses
Visualization of income flow from segment revenue to net income